2,3,4,5,6-pentahydroxybenzoic acid | 145279-23-8

• 分子结构分类: 有机化合物 - 脂质和类脂质分子 - 异戊烯醇脂质
• 英文名称: 2,3,4,5,6-pentahydroxybenzoic acid
• 英文别名: ellagoic acid；Benzoic acid, pentahydroxy-
• CAS: 145279-23-8
• 化学式: C₇H₆O₇
• 分子量: 202.12
• InChiKey: ZHDKFKAWPYRHSQ-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  0.8
• 重原子数：
  14
• 可旋转键数：
  1
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  138
• 氢给体数：
  6
• 氢受体数：
  7

反应信息

• 作为产物：
  描述：

  1-O-galloyl-4,6-hexahydroxybenzoyl-β-D-glucose 生成 D-葡萄糖 、 没食子酸 、 2,3,4,5,6-pentahydroxybenzoic acid
  参考文献：
  名称：

  Phenolic compounds fromOenothera gigas

  摘要：

  DOI：

  10.1007/bf02234915

文献信息

• [EN] PROCESS FOR THE PREPARATION OF ORGANIC BROMIDES<br/>[FR] PROCÉDÉ DE PRÉPARATION DE BROMURES ORGANIQUES
  申请人：TECHNION RES & DEV FOUNDATION

  公开号：WO2017060905A1

  公开（公告）日：2017-04-13

  The present invention provides a process for the preparation of organic bromides, by a radical bromodecarboxylation of carboxylic acids with a bromoisocyanurate.

  本发明提供了一种有机溴化物的制备方法，通过使用溴异氰酸酯对羧酸进行自由基溴脱羧化反应。
• [EN] PROCESS FOR THE PREPARATION OF ORGANIC HALIDES<br/>[FR] PROCÉDÉ DE PRÉPARATION D'HALOGÉNURES ORGANIQUES
  申请人：TECHNION RES & DEV FOUNDATION

  公开号：WO2017060906A1

  公开（公告）日：2017-04-13

  The present invention provides a halo-de-carboxylation process for the preparation of organic chlorides, organic bromides and mixtures thereof, from their corresponding carboxylic acids, using a chlorinating agent selected from trichloroisocyanuric acid (TCCA), dichloroisocyanuric acid (DCCA), or combination thereof, and a brominating agent.

  本发明提供了一种卤代羧酸脱羧化工艺，用于从相应的羧酸制备有机氯化物、有机溴化物及其混合物，所述工艺使用从三氯异氰酸（TCCA）、二氯异氰酸（DCCA）或其组合中选取的氯化试剂和溴化试剂。
• RESIST COMPOSITION, METHOD OF FORMING RESIST PATTERN, AND COMPOUND
  申请人：TOKYO OHKA KOGYO CO., LTD.

  公开号：US20200183273A1

  公开（公告）日：2020-06-11

  A resist composition including a base material component (A) whose solubility in a developing solution is changed due to the action of an acid, and a compound (D0) formed of an anion moiety and a cation moiety which is represented by Formula (d0), in which the cation moiety of the compound (D0) has a Log P value of less than 7.7. In the formula, M m+ represents an m-valent organic cation, R d0 represents a substituent, p represents an integer of 0 to 3, q represents an integer of 0 to 3, n represents an integer of 2 or greater, and a relationship of “n+p≤(q×2)+5” is satisfied.

  一种抗蚀组合物，包括一种基材料组分（A），由于酸的作用而在显影液中溶解性发生改变，以及由阴离子基团和由公式（d0）表示的阳离子基团组成的化合物（D0）。其中，化合物（D0）的阳离子基团的Log P值小于7.7。在公式中，Mm+表示m价有机阳离子，Rd0表示取代基，p表示0到3之间的整数，q表示0到3之间的整数，n表示大于等于2的整数，并且满足“n+p≤（q×2）+5”的关系。
• Iron(II)-Containing Treatments for Hyperphosphatemia
  申请人：Huval Chad

  公开号：US20100135950A1

  公开（公告）日：2010-06-03

  A pharmaceutical composition comprises a pharmaceutically acceptable ferrous iron compound; an amine polymer or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier. Alternatively, a pharmaceutical composition comprises a pharmaceutically acceptable ferrous iron compound and pharmaceutically acceptable carrier, wherein the ferrous iron compound is selected from the group consisting of iron(II) acetate, iron(II) citrate, iron(II) ascorbate, iron(II) oxalate, iron(II) oxide, iron(II) carbonate, iron(II) carbonate saccharated, iron(II) formate, iron(II) sulfate, iron(II) chloride, iron(II) acetylacetonate and combinations thereof. A method of treating a subject with hyperphosphatemia comprises administering to the subject an effective amount of a pharmaceutical composition as described above.

  一种药物组合物包括：药学上可接受的二价铁化合物；一种胺基聚合物或其药学上可接受的盐，以及一种药学上可接受的载体。或者，一种药物组合物包括：药学上可接受的二价铁化合物和药学上可接受的载体，其中，所述二价铁化合物选自以下组合：铁(II)醋酸盐、铁(II)柠檬酸盐、铁(II)抗坏血酸盐、铁(II)草酸盐、铁(II)氧化物、铁(II)碳酸盐、铁(II)碳酸盐糖化物、铁(II)甲酸盐、铁(II)硫酸盐、铁(II)氯化物、铁(II)乙酰丙酮酸盐及其组合物。一种治疗高磷血症患者的方法包括向患者施用上述药物组合物的有效量。
• Iron(II)-Containing A Treatments for Hyperphosphatemia
  申请人：Huval Chad

  公开号：US20130243720A1

  公开（公告）日：2013-09-19

  A pharmaceutical composition comprises a pharmaceutically acceptable ferrous iron compound; an amine polymer or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier. Alternatively, a pharmaceutica composition comprises a pharmaceutically acceptable ferrous iron compound and pharmaceutically acceptable carrier, wherein the ferrous iron compound is selected from the group consisting of iron(II) acetate, iron(II) citrate, iron(II) ascorbate, iron(II) oxalate, iron(II) oxide, iron(II) carbonate, iron(II) carbonate saccharated, iron(II) formate, iron(II) sulfate, iron(II) chloride, iron(II) acetylacetonate and combinations thereof. A method of treating a subject with hyperphosphatemia comprises administering to the subject an effective amount of a pharmaceutical composition as described above.

  一种药物组合物包括一种药学上可接受的亚铁铁化合物；一种胺基聚合物或其药学上可接受的盐，以及一种药学上可接受的载体。另外，一种药物组合物包括一种药学上可接受的亚铁铁化合物和药学上可接受的载体，其中所述亚铁铁化合物选自以下组合：铁（II）醋酸盐，铁（II）柠檬酸盐，铁（II）抗坏血酸盐，铁（II）草酸盐，铁（II）氧化物，铁（II）碳酸盐，铁（II）碳酸盐糖化物，铁（II）甲酸盐，铁（II）硫酸盐，铁（II）氯化物，铁（II）乙酰丙酮酸盐及其组合物。一种治疗高磷血症的方法包括向受试者投与上述药物组合物的有效量。